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Abstract
Background: Normal bronchial tissue expression of GRPR, which encodes the gastrin-releasing peptide receptor,
has been previously reported by us to be associated with lung cancer risk in 78 subjects, especially in females. We
sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-
control study where adjustments could be made for tobacco exposure and sex.
Methods: We evaluated GRPR mRNA levels in histologically normal bronchial epithelial cells from 224 lung cancer
patients and 107 surgical cancer-free controls. Associations with lung cancer were tested using logistic regression
models.
Results: Bronchial GRPR expression was significantly associated with lung cancer (OR = 4.76; 95% CI = 2.32-9.77) in
a multivariable logistic regression (MLR) model adjusted for age, sex, smoking status and pulmonary function. MLR
analysis stratified by smoking status indicated that ORs were higher in never and former smokers (OR = 7.74; 95%
CI = 2.96-20.25) compared to active smokers (OR = 1.69; 95% CI = 0.46-6.33). GRPR expression did not differ by
subject sex, and lung cancer risk associated with GRPR expression was not modified by sex.
Conclusions: GRPR expression in non-cancerous bronchial epithelium was significantly associated with the
presence of lung cancer in never and former smokers. The association in never and former smokers was found in
males and females. Association with lung cancer did not differ by sex in any smoking group.
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Background
Lung cancer incidence rates have been declining for
men since the 1980s. However, incidence rates for
women over 65 have been increasing or have remained
steady during this same time period [1]. Though tobacco
use is a significant risk factor for lung cancer, 15-20% of
lung cancer patients are lifetime never-smokers. Our
group previously reported that bronchial epithelium
expression of GRPR, which encodes the gastrin-releasing
peptide receptor (GRPR), was associated with a diagno-
sis of lung cancer in female never smokers [2]. GRPR is
an X-linked gene that has been reported to escape
X-inactivation [3]. This finding raised the possibility that
increased GRPR expression in women accounted for
some of the increased incidence rates of lung cancer in
never smokers who are female, compared to never
smoking men, which was recently reported in a large
prospective cohort study [4]. Since GRPR stimulation
induces proliferative effects in bronchial cells [5], it is
possible that activation of this pathway is a risk factor
for lung cancer separate from that of tobacco exposure.
GRPR is overexpressed in lung cancers and in head
and neck squamous cell carcinoma (HNSCC) [6,7]. We
have previously reported elevated levels of GRPR mRNA
in lung cancers and HNSCC [6,8]. In addition to can-
cer-specific overexpression of GRPR, we have demon-
strated that mucosal tissues adjacent to HNSCC have
GRPR mRNA levels reflective of the adjacent HNSCC
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tumor [6]. These findings suggest that elevated GRPR
mRNA in normal bronchial epithelia may be associated
with lung cancer risk and/or may indicate the presence
of lung cancer.
We undertook a case-control study to determine
whether elevated GRPR mRNA expression in normal,
at-risk epithelium correlated with the presence of lung
cancer. We evaluated the association between GRPR
mRNA expression in purified cultured normal bronchial
epithelial cells and the presence of lung cancer. Our pri-
mary finding was the observed increased expression of
GRPR in normal bronchial epithelia in lung cancer cases
compared to cancer-free controls. The impact of this was
highest in subjects who never smoked or who had under-
gone smoking cessation before diagnosis. The association
was found in both male and female never smokers, sug-
gesting GRPR plays a similar role in development of lung
cancer in men and women. The result of this study high-
lights GRPR overexpression in normal epithelial mucosa
as a candidate risk factor for lung cancer, especially in
those with limited tobacco exposure.
Methods
Lung cancer case-control study subjects and tissues
Lung cancer cases (n = 224) and surgical control sub-
jects (n = 107) enrolled in prospective thoracic surgical
tissue collection protocols from 1992-2004 donated
mainstem bronchus biopsy specimens obtained at the
time of resection, bronchoscopy, or lung transplant.
Questionnaire and pulmonary function tests were admi-
nistered prior to surgery, and forced expiratory volume
in the first second (FEV1) and forced vital capacity
(FVC) were used to assess airway obstruction [9]. Parti-
cipants were patients with suspected lung cancer who
underwent bronchoscopic or thoracic procedures. Cases
had confirmed diagnoses of primary lung cancer while
controls had non-cancerous diagnoses. Diagnoses occur-
ring in 5% or more of surgical control subjects included
the following: 15 had no diagnosis of disease (14%), 12
had emphysema (11%), 12 had a granuloma (11%), 11
had alpha-1 antitrypsin deficiency (10%), 7 had pulmon-
ary hypertension (9%), 7 had a benign growth (7%), 6
had a lung obstruction (6%), 5 had cystic fibrosis (5%), 5
had a hamartoma (5%) and 5 had pulmonary fibrosis
(5%). Two of the 15 control subjects with no diagnosis
of disease were lung donors. Tissues from 219 of the
224 cases and 89 of the 107 controls were prospectively
collected under protocols approved by the University of
Pittsburgh institutional review board (IRB). In a coop-
erative effort, tissues from 5 of the 224 cases and 18 of
the 107 controls were prospectively collected under a
surveillance bronchoscopy protocol approved by the
University of Colorado IRB. The case-control study
populations are described in Table 1. Primary bronchial
epithelial cell culture procedures were used to obtain
proliferating bronchial epithelial cells as described pre-
viously [5]. Bronchial epithelial cell cultures were har-
vested at passage 1 for GRPR mRNA expression studies.
Detection of GRPR expression in bronchial epithelial cells
RNA isolation from bronchial cells and detection of
GRPR gene expression was performed as previously
described [5]. PCR amplification was performed following
oligo-dT-primed reverse transcription (RT) of total RNA
using primers GRPR-1 (5’-CTCCCCGTGAACGAT-
GACTGG-3’) and GRPR-2 (5’-ATCTTCATCAGGG-
CATGGGAG-3’). Presence of GRPR product was
evaluated by hybridization with a 32P-labeled internal
probe (5’-CACCTCCATGCTCCACTTTGTC-3’). The
GAPDH gene expression was also evaluated in order to
assess RNA integrity and success of the reverse transcrip-
tion step. GAPDH was successfully amplified from RNA
isolated from all cases and controls.
Statistical Analyses
In order to test the association of sex and other vari-
ables with GRPR bronchial expression, candidate con-
founding variables including age, sex, ethnicity, smoking
status, pack-years of tobacco-use (py), and pulmonary
function were evaluated for association with GRPR
expression separately for cases and controls for each
case-control study using the chi-square test, Fisher’s
exact test, or Wilcoxon rank sum test as appropriate.
All P values reported were 2-sided with significance
defined by P < 0.05.
Evaluating GRPR expression in non-cancerous bron-
chial epithelia among cases versus controls was the pri-
mary endpoint of the study. Univariate and multivariable
logistic regression models were implemented to assess
the significance of the association of GRPR bronchial
expression with cancer before and after controlling for
other important variables. For these models, age and sex
were defined a priori to be included. Sex, ethnicity and
smoking status were treated as categorical variables, age
and pack-years as continuous variables, and pulmonary
function as an ordinal variable. The likelihood ratio test
was used to test the goodness of fit of logistic regression
models. To assess whether the association between bron-
chial GRPR expression and lung cancer was modified by
sex, a sex by GRPR expression interaction term was eval-
uated for significance in the multivariable logistic regres-
sion model. Because disease etiology likely differs for
never smokers compared to smokers, a stratified analysis
by smoking status was also performed.
Association of GRPR expression with overall survival,
defined as time from surgery to death, was analyzed
using Cox proportional hazards models. Date of surgery,
death, and last follow-up were provided by the University
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of Pittsburgh Cancer Institute (UPCI) Lung Cancer
Registrar. Hazard ratios associated with GRPR expression
were estimated using multivariable Cox proportional
hazards models. The assumption of proportional hazards
was assessed for all Cox models by evaluation of scaled
Schoenfeld residuals.
Results
GRPR expression in bronchial epithelia was more
frequent in lung cancer patients than cancer-free control
subjects
Presence or absence of GRPR mRNA in non-cancerous
bronchial epithelial cells derived from mainstem
Table 1 Characteristics of Lung Cancer Cases and Controls
Characteristic Lung Cancer Cases (N = 224) Cancer-free Controls (N = 107) P
Age, y
Median (Range) 68 (40-85) 52 (31-83) < 0.001†
Sex, N %
Male 105 46.9% 60 56.1% 0.12‡
Female 119 53.1% 47 43.9%
Ethnicity, N %
Caucasian 212 95.5% 101 94.4% 0.70§
African-American 9 4.1% 5 4.7%
Other 1 0.5% 1 0.9%
Smoking Status, N %
Never smoker 19 8.5% 33 30.8% < 0.001‡
Ex-smoker 111 49.6% 57 53.3%
Active smoker 87 38.8% 14 13.1%
Unknown 7 3.1% 3 2.8%
Pack-Years
Median (Range) 50 (0-150) 25 (0-156) < 0.001†
Unknown 0-150 0-156
Lung Function, N %
Normal 89 39.7% 36 33.6% < 0.001§
Mild Obstruction 14 6.3% 5 4.7%
Moderate Obstruction 52 23.2% 16 15.0%
Severe Obstruction 37 16.5% 46 43.0%
Unknown 32 14.3% 4 3.7
Tumor Type, N %
Adenocarcinoma 112 50.0% -
Squamous cell carcinoma 60 26.8% -
Other NSCLC 27 12.1% -
Small cell lung cancer 10 4.5% -
Other/unknown 15 6.7% -
Stage, N %
TIS-I 99 44.2% -
II 38 17.0% -
III 49 21.9% -
IV 16 7.1% -
Not Staged 22 9.8% -
Follow-up, N %
Alive 78 34.8% -
Dead 142 63.4% -
Median survival, months# 35.8 -
(95% CI) (31.7-40.5) -
#Median overall survival for cancer cases alive at last follow-up
†Rank sum test
‡Chi-square test
§Fisher’s exact test
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bronchus airway biopsies of lung cancer cases (n = 224)
and cancer-free controls (n = 107) (Table 1) was
assessed by RT-PCR followed by hybridization with a
radio-labeled probe in order to maximize sensitivity.
Because the airway biopsy analysis of this cohort began
before quantitative PCR (q-PCR) was available, the
RT-PCR semi-quantitative technique was used through-
out the lung cancer case-control study to maintain con-
sistency and power. Of the 224 lung cancer cases
evaluated, 158 (71%) had GRPR expression in bronchial
cells. In contrast, only 41 (38%) of the 107 cancer-free
surgical controls had detectable GRPR bronchial
expression.
GRPR expression has been reported to be elevated with
tobacco use. We tested for association between GRPR
expression in non-cancerous surrogate tissues and smok-
ing status and pack-years of tobacco use stratified by can-
cer status. Among never and former smokers, lung
cancer patients more frequently had detectable GRPR
expression while the frequency of detected GRPR mRNA
was similar for actively smoking lung cancer cases and
controls (Table 2). We observed a statistically significant
association between GRPR expression in bronchial
mucosa and smoking status among lung cancer patients
(P = 0.03, Table 2) with overrepresentation of GRPR
bronchial expression among never smoking lung cancer
patients. GRPR bronchial expression was also associated
with smoking status among cancer-free surgical controls
with an overrepresentation of GRPR bronchial expression
among active smokers (P = 0.02) (Table 2). Only a min-
ority of the never smoker and former smoker surgical
cancer-free control subjects had GRPR bronchial expres-
sion while, the majority of actively smoking surgical con-
trols had detectable GRPR bronchial expression. Though
there was a significant association between GRPR expres-
sion and smoking status for cases and controls, in the
analyses stratified by case status we found no statistically
significant association between pack-years of smoking
and GRPR expression in cases or controls (Table 2).
Bronchial GRPR expression was not associated with sex,
ethnicity or pulmonary function in lung cancer cases or
controls
In order to assess the association of subject characteris-
tics with GRPR expression independent of cancer, a
stratified analysis by case status was performed sepa-
rately for the lung cancer case and control populations.
We hypothesized that GRPR expression would differ by
sex because GRPR resides on the portion of the X chro-
mosome reported to escape X-inactivation [3], and we
had previously reported that GRPR expression in bron-
chial tissues was more frequent in women never smo-
kers than men never smokers in a study involving 78
subjects [2].
In this larger study involving 331 subjects, in addition
to evaluating differences in GRPR expression by sex, we
also tested the association between GRPR expression and
age, ethnicity and pulmonary function. GRPR bronchial
expression levels did not differ by sex, ethnicity or pul-
monary function for either lung cancer cases or controls
(Table 2). However, lung cancer cases positive for GRPR
expression were statistically younger than GRPR negative
cases (Table 2).
Evaluating the GRPR expression distribution among
surgical cancer-free controls by benign diagnosis, we
observed a trend towards a significant association (p =
0.065, Fisher’s exact test) with deviations from the aver-
age 38% GRPR positive frequency being most apparent
for diagnoses of alpha-1 trypsin deficiency (1 of 11 sub-
jects were GRPR positive) and granuloma (9 of 12 sub-
jects were GRPR positive). Only two of the 9 GRPR
positive granuloma subjects were active smokers. This
trend towards increased bronchial GRPR expression in
subjects with granuloma that did not reach statistical
significance suggests the possibility that inflammation-
induced tissue damage and/or wound repair in response
to damage may be associated with bronchial GRPR
expression. We did not find evidence of an association
between bronchial GRPR expression and hyperprolifera-
tive disorders among the cancer-free control subjects.
GRPR expression levels did not reflect disease stage or
tumor type
In order to determine whether GRPR expression differed
by tumor clinical and/or pathological characteristics, we
tested for association between tumor characteristics and
bronchial GRPR expression in lung cancer cases. The
distribution of lung cancer cases by clinical stage and
tumor histology is provided in Table 1. Bronchial GRPR
expression in non-cancerous mucosa was independent
of disease stage (P = 0.49, Table 2) and tumor histology
(P = 0.50, Table 2).
GRPR expression in non-cancerous bronchial mucosal
tissues was significantly associated with lung cancer
independent of age, sex and smoking status
Detection of GRPR mRNA in bronchial tissues was sig-
nificantly associated with presence of lung cancer (O.R
= 3.85; 95% CI = 2.37-6.25) (All Subjects, Figure 1).
Even after controlling for possible confounding effects
of age, sex, smoking status and pulmonary function
expression of GRPR in normal bronchial epithelium
remained significantly associated with lung cancer (O.R.
= 4.76; 95% CI = 2.32-9.77) (All Subjects, Figure 1).
GRPR was previously reported by our group in a study
of 78 subjects to be more frequently expressed in
women with lung cancer than in men with lung cancer
[2], suggesting the possibility that this differential
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expression may account at least in part for the heigh-
tened smoking-related lung cancer risk for women
observed in some studies [10,11]. However, in this larger
study, the pair-wise interaction between sex and GPRR
expression was found not to be significant (P = 0.31) in
a multivariable logistic regression model also containing
age, sex, pulmonary function and bronchial GRPR
expression. Therefore, this study did not support our
previous hypothesis that GRPR expression among
women contributed to their increased lung cancer risk.
Rather, it suggested that never smoking status was a
confounder in our previous analysis, since the majority
of never smokers diagnosed with lung cancer are female.
GRPR expression in bronchial epithelium was significantly
associated with lung cancer among never smokers and
former smokers but not active smokers
Molecular alterations differ markedly for tobacco-related
versus non-tobacco-related lung cancers [12,13]. These
finding indicate that disease etiology for lung cancer
varies by tobacco-use history. A stratified analysis by
smoking status indicated that presence of GRPR expres-
sion in bronchial cells was significantly associated with
lung cancer for never smokers (O.R. = 17.0; 95% C.I =
3.32-87.13) and former smokers (O.R. = 3.69; 95% C.I =
1.88-7.29) but not active smokers (O.R. = 1.18; 95% CI
= 0.34-4.15) (Figure 1), and these odds ratios differed
Table 2 Evaluation of association between GRPR broncial expression and demographic and risk factors stratified by
lung cancer case status.
Lung Cancer Cases Controls
Characteristic Total GRPR Positive GRPR Negative P Total GRPR Positive GRPR Negative P
N 224 158 70.5% 66 29.5% 107 41 38.3% 66 61.7%
Age
Median (Range) 224 67 (42-84) 70 (41-85) 0.01*† 52 (31-80) 52 (31-83) 0.44†
Sex
Male 105 75 71.4% 30 28.6% 0.78‡ 60 20 33.3% 40 66.7% 0.23‡
Female 119 83 69.7% 36 30.3% 47 21 44.7% 26 55.3%
Ethnicity
Caucasian 213 150 70.4% 63 29.6% 1.00§ 101 38 37.6% 63 62.4% 0.67§
Non-Caucasian 10 7 70.0% 3 30.0% 6 3 50.0% 3 50.0%
Smoking Status
Never Smoker 19 17 89.5% 2 10.5% 0.03*§ 33 11 33.3% 22 66.7% 0.02*§
Former Smoker 111 70 63.1% 41 36.9% 57 18 31.6% 39 68.4%
Active Smoker 87 65 74.7% 22 25.3% 14 10 71.4% 4 28.6%
Pulmonary Function
Normal 89 62 69.7% 27 30.3% 0.52§ 36 18 50.0% 18 50.0% 0.22§
Mild Obstruction 14 9 64.3% 5 35.7% 5 2 40.0% 3 60.0%
Moderate Obstruction 52 37 71.2% 15 28.8% 16 5 31.3% 11 68.8%
Severe Obstruction 37 30 81.1% 7 18.9% 46 13 28.3% 33 71.7%
Pack-Years
Median (Range) 222 50 (0-150) 50 (0-120) 0.94† 40 (0-110) 25 (0-156) 0.11†
Disease Stage
CIS 1 1 100.0% 0 0.0% 0.49§ - - - -
1 98 69 70.4% 29 29.6% - - -
2 38 24 63.2% 14 36.8% - - -
3 49 39 79.6% 10 20.4% - - -
4 16 11 68.8% 5 31.3% - - -
Histology
Adenocarcinoma 112 74 66.1% 38 33.9% 0.50§ - - - -
Squamous cell carcinoma 60 47 78.3% 13 21.7% - - -
Other NSCLC 27 19 70.4% 8 29.6% - - -
Small cell lung cancer 10 8 80.0% 2 20.0% - - -
Other/unknown 15 10 66.7% 5 33.3% - - -
*Significant at P < 0.05
† Wilcoxon rank sum test
‡ Chi-square test
§ Fisher’s exact test
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significantly (P < 0.001, Mantel-Haenszel test of homo-
geneity (M-H test)). The association between GRPR
bronchial expression and lung cancer among never smo-
kers and former smokers was significant even after con-
trolling for the effects of age, sex, and pulmonary
function (Figure 1). The combined, adjusted odds ratio
for never and former smokers, which were found to not
differ significantly (P = 0.09; M-H test), was 7.74 (95%
CI = 2.96-20.25). A trend towards higher odds ratios
with fewer pack-years of tobacco use was observed
when the analysis was stratified by tertiles of control
subject pack-year use (data not shown); however, the
odds ratios did not differ significantly by tertile pack-
year category.
Because we hypothesized that GRPR expression in
bronchial epithelia would contribute to increased risk of
lung cancer for women never smokers compared to
men never smokers, we tested the interaction between
sex and GRPR expression status for association with
lung cancer in the never smoking stratum. We found
the GRPR expression by sex interaction to not be signifi-
cantly associated with lung cancer among never smokers
in a multiple logistic regression model also containing
age, sex and pulmonary function (P = 0.94). Because the
number of never smokers in our study was not large
(n = 52) and the association between GRPR expression
and lung cancer did not differ significantly between
never and former smokers, we also tested the GRPR
expression by sex interaction for significance for never
and former smokers. We found that the GRPR
expression by sex interaction was also not significant in
this same model when evaluating never and former
smokers (P = 0.47).
GRPR expression in surrogate tissues was not a
prognostic indicator for survival in lung cancer cases
Because GRPR expression in bronchial epithelia was
associated with lung cancer, we hypothesized that for
cases with detectable bronchial GRPR expression, survi-
val would be reduced compared to cases without detect-
able GRPR expression. However, the presence of GRPR
mRNA in bronchial cells was not an indication of over-
all lung cancer survival. The hazards ratio for overall
lung cancer survival in Cox models adjusted for age,
sex, and disease stage was 0.87 (95% CI = 0.57-1.34) for
patients with GRPR bronchial expression compared to
patients without detectable GRPR bronchial expression.
Discussion
In lung cancer GRPR and its ligand are involved in
autocrine growth stimulation [6,14]. Previous results
showed that lung tumor tissues have elevated GRPR
expression, and we have previously described elevated
GRPR mRNA levels in histologically normal mucosal tis-
sues adjacent to HNSCC compared to oral mucosal tis-
sues from cancer-free control subjects [6]. GRPR mRNA
expression has also been detected in prostate tumors
and tissues adjacent to prostate cancers [15]. Our new
findings reported here indicate that in a prospectively
collected lung cancer case-control population, GRPR
Bronchial GRPR 
Expression 
Cases  
N
Controls  
N
Unadjusted O.R.†
(95% CI) P
Adjusted O.R.        
(95% CI) P
All Subjects
Negative 66 66 1.0 reference 1.0 reference
Positive 158 41 3.85 (2.37-6.25) <0.001 4.76 (2.32-9.77) ‡ <0.001
Total 224 107
Never Smokers
Negative 2 22 1.0 reference 1.0 reference
Positive 17 11 17.00 (3.32-87.13) 0.001 17.80 (1.51-210.54) § 0.022
Total 19 33
Former Smokers
Negative 41 39 1.0 reference 1.0 reference
Positive 70 18 3.69 (1.88-7.29) <0.001 8.73 (2.72-28.03) § <0.001
Total 111 57
Active Smokers
Negative 22 4 1.0 reference 1.0 reference
Positive 65 10 1.18 (0.34-4.15) 0.794 1.69 (0.46-6.33) § 0.430
T t l 87 14o a
† Univariate logistic regression model odds ratio (O.R.)
‡ Multivariable logistic regression model odds ratio (O.R.) adjusted for age, sex, smoking    
status, pulmonary function
§ Stratified m lti ariable logistic regression model odds ratio (O R ) adj sted for age seu v . . u , x,
pulmonary function
Figure 1 GRPR expression in bronchial epithelia is significantly associated with lung cancer among never and former smokers.
Univariate and multivariable logistic regression analysis estimates of odds ratios are provided for all subjects, and separate analyses are provided
by smoking status.
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expression in at-risk upper aerodigestive mucosa was
significantly associated with lung cancer. Importantly,
even after controlling for the effects of possible con-
founding by age, sex, and tobacco use, GRPR expression
in non-cancerous mucosal tissues was significantly asso-
ciated with lung cancer among never and former smo-
kers and appeared to confer similar risk to both sexes.
Our finding here of no difference in bronchial epithe-
lial cell GRPR expression between men and women did
not replicate our previous result [2]. In our previous
bronchial cell study, which had a smaller sample size of
78 patients, the presence of cancer was not separately
evaluated, and only one never smoker with lung cancer
was male [2]. In retrospect, it is likely that the associa-
tions between GRPR expression, female sex, and smok-
ing observed in our previous study were actually
surrogates for the underlying association between bron-
chial epithelial GRPR expression and lung cancer, which
appears to be most significant in never smokers. There-
fore, this study presents important revisions to our pre-
vious understanding of the role of GRPR in lung cancers
arising in females and males; this study supports a simi-
lar role for bronchial GRPR mRNA expression and lung
cancer risk for both females and males.
Although in the current study we also found no asso-
ciation between GRPR expression and pack-years of
smoking, we did observe associations between smoking
status (active versus former smoker versus never smo-
ker) and GPRR expression. We observed these associa-
tions for both cases and controls separately, but the
relationships were different. The proportion of GRPR
positive actively smoking cancer-free control subjects
was similar to the proportion of actively smoking lung
cancer cases. These findings were consistent with our
previously reported findings that GRPR expression in
bronchial epithelium was activated with tobacco use [2]
and with findings that bombesin-like peptide receptors
play a role in wound healing following airway injury
[16]. Similar to our previous findings of persistent bron-
chial GRPR expression after tobacco cessation [5], we
detected bronchial GRPR expression in the majority of
former smoking lung cancer cases. In contrast, in the
current study bronchial GRPR expression was detected
in only a minority of cancer-free controls who were for-
mer smokers. The inclusion of more cancer-free control
subjects in this study compared to our 1997 study has
allowed us to evaluate lung cancer patients and cancer-
free controls separately and has revealed new insights
regarding the relationship between bronchial GRPR
expression and tobacco use in cancer-free controls.
Although the number of active smoking surgical con-
trols in our current study was small, the data suggest that
bronchial GRPR expression may be induced by tobacco
use in subjects without lung cancer, but that the increase
in GRPR expression in bronchial mucosa likely subsides
following the cessation of smoking in most subjects with-
out lung cancer. Among former smoking lung cancer
cases, bronchial GRPR expression may be aberrantly
maintained following cessation of smoking, or similar to
never smoking lung cancer cases, bronchial GRPR
expression may reflect risk that is independent of tobacco
use. Our 1997 report indicated that of the 4 cancer-free
subjects with defined bronchial GRPR expression and
smoking status, 1 active smoker was GRPR positive while
3 subjects who were former or never smokers were nega-
tive for GRPR expression. Therefore, although the num-
bers are small, among cancer-free control subjects, the
relationship between smoking status and bronchial GRPR
expression in the 1997 study is consistent with our cur-
rent study results.
Of special interest was the finding of frequent bron-
chial GRPR expression among never smoking lung cancer
cases. While GRPR expression was detected in only a
minority of never smoking cancer-free controls, GRPR
expression was detected in almost 90% of never smoking
lung cancer cases. Though the specific cause of GRPR
expression in never smoking lung cancer cases is
unknown, we posit that bronchial GRPR expression may
reflect an inherent or conferred risk factor that can be
best observed in the absence of the more potent risk fac-
tor of tobacco use. Though bronchial GRPR expression
was more common among cancer-free controls with a
diagnosis of granuloma, suggesting a possible inflamma-
tory component to bronchial GRPR expression among
cancer-free controls, bronchial GRPR expression was not
increased in lung cancer cases or controls with more
severe pulmonary obstruction, which also has an inflam-
matory component. Therefore, the role of inflammation
in elevated bronchial GRPR expression remains
undefined.
GRPR expression in normal bronchial tissues was not
correlated with clinical disease stage. Therefore, our
data suggest that GRPR expression in surrogate tissues
did not reflect tumor burden and, perhaps, was not a
direct consequence of the prevalent cancer. Our finding
that detectable GRPR expression in normal upper aero-
digestive tissues was not an indication of poor overall
survival for lung cancer cases indicates that elevated
GRPR bronchial cell expression was not associated with
disease progression and is, instead, likely to be a marker
of risk exposure or a marker of host susceptibility.
Lung cancer cases positive for GRPR bronchial expres-
sion were significantly younger than cases negative for
GRPR expression, which supports the role of GRPR bron-
chial expression as conferring lung cancer risk. Though a
prospective cohort study will be required to fully under-
stand the relationship between GRPR expression levels in
surrogate tissues and the development of lung cancer,
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GRPR expression in normal bronchial tissues has poten-
tial value as a marker for elevated risk, especially in those
with little or no tobacco exposure. Though GRPR is over-
expressed in many solid tumors, only one other group
has evaluated GRPR, GRP and/or their gene product
levels in surrogate tissues of cancer patients to date.
Uchida et al. reported that serum levels of proGRP, as
measured by enzyme-linked immunosorbent assay
(ELISA), correlated with tumor GRP gene expression
levels in small cell lung cancer (SCLC) patients [17].
GRPR expression levels in tumors were not evaluated in
our study, as material for analysis was not available.
The increased risk due to elevated GRPR expression
may be most apparent in never and former smokers
because the contribution of GRPR expression to risk is
obscured in active smokers by factors such as genetic
abnormalities and inflammatory processes that confer
substantial risk from tobacco use. Elevated GRPR expres-
sion in the lung may independently contribute to
increased cancer risk by promoting proliferation. GRPR
is expressed at early embryonic stages in the nervous,
urogenital, respiratory, and gastrointestinal systems and
expression in these tissues is generally down-regulated
before birth [18-20]. The GRPR ligand, GRP, a bombe-
sin-like peptide (BLP) growth factor, is expressed by pul-
monary neuroendocrine cells and has been shown to
stimulate lung development in utero and to increase
growth and maturation of human fetal lung organ cul-
tures [20,21]. In non-cancerous tissues, BLPs stimulate
growth of bronchial, gastrointestinal and pancreatic
epithelial cells and lead to ligand-dependent hyperplasia
[5,19,22-24]. GRPR and GRP are involved in an autocrine
stimulation loop in lung cancer and HNSCC [6,14], and
GRPR expression has been shown to be positively regu-
lated by GRP [20]. Increased GRPR expression in the
lung may, therefore, reflect a state that is more nascent
and proliferative in nature than epithelium with low or
undetected GRPR expression.
We acknowledge our case-control study population
limitations. This case-control study required hospital
surgical controls, and this limited recruitment with the
result that our lung cancer cases are older than our con-
trols and include fewer men. In addition, the exhaustion
of samples made quantitative measurements of GRPR
mRNA expression impossible. We have confined our
analysis to GRPR mRNA because of antibody reagent
limitations at the time the samples were evaluated. This
leaves the question of whether GRPR protein levels also
differ unanswered. Despite these limitations, a high
degree of association between detectable GRPR expres-
sion in normal bronchial tissue and lung cancer was
demonstrated in the case-control population even after
adjusting for sex and age.
Though we did not assess the epidermal growth factor
receptor (EGFR) mRNA or protein expression in bron-
chial epithelial cultures, we speculate that increased
GRPR expression contributes to lung cancer through
EGFR-dependent and/or -independent mechanisms. The
EGFR pathway has been reported to be activated in lung
tumors from never smokers with EGFR mutations, and
it is possible that lung tumors developing in never smo-
kers have multiple mechanisms for EGFR activation.
The GRPR pathway is known to interact with the EGFR
pathway in lung cancer cells by increasing the release of
EGFR ligands such as amphiregulin [8], which could act
to further promote cancer in never smokers who
develop EGFR mutations. Alternatively, activation of the
GRPR pathway may increase EGFR bronchial cell signal-
ing in the absence of EGFR mutation, providing another
route to lung cancer development in never smokers.
Conclusions
The GRPR pathway may activate proliferative pathways
that increase the likelihood of lung cancer development
in male and female former and never smokers. We con-
clude from our data that GRPR expression likely does
not contribute to sex differences in rates of lung cancer
incidence in never or former smokers.
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